Home > Insider Trading > Filing (0000890465-13-000029)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
890465	Nps Pharmaceuticals Inc	NPSP	Biological Products, (No Disgnostic Substances) (2836)	870439579

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1192128	M Luke Beshar	550 Hills Drive Bedminster NJ 07921	Evp & Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-12-12	39,530	$8.25	98,710	No	4	M	Direct
Common Stock	Acquisiton	2013-12-12	20,781	$8.21	119,491	No	4	M	Direct
Common Stock	Disposition	2013-12-12	60,311	$24.02	59,180	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options	Disposition	2013-12-12	39,530	$0.00	39,530	$8.25
Common Stock	Stock Options	Disposition	2013-12-12	20,781	$0.00	20,781	$8.21

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
17,970		2021-02-17	No	4	M	Direct
26,719		2022-02-07	No	4	M	Direct

Footnotes

The shares were sold pursuant to a predefined price target in a trading plan qualified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, that was effective December 12, 2013.
The price shown above represents the weighted average price of the shares sold. The range of sales prices was $24.00 and $24.11. The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC Staff, upon request, information regarding the number of shares sold at each price within the range of prices actually paid.
On February 17, 2011, the Reporting Person received a grant of 57,500 stock options under the Issuer's 1998 Stock Option Plan. The options become exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter. As of the date of this filing, 39,530 stock options have vested.
On February 7, 2012, the Reporting Person recevied a grant of 47,500 stock options under the Issuer's Stock 2005 Stock Option Plan. The options become exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25%, every three months thereafter. As of the date of this filing, 20,781 stock options have vested.